The inheritance of mutated BRCA1 and BRCA2 genes confer a very high risk for developing breast cancer and ovarian cancer. Since these genes were identified in the mid-1990’s genetic testing and counseling services have been available to identify women at high risk for these cancers in order to offer cancer surveillance and prevention options. Recently new cancer therapies have been proposed for affected mutations carriers that take advantage of defects occurring as a result of mutations in the BRCA1 and BRCA2 genes. Therapies tailored to genetic background has been proposed as new treatment strategies to improve overall outcome. This proposal describes experiments aimed at investigating how many women with ovarian cancer might benefit from such specific therapies by determining the number of mutation carriers at a specific clinic. Our results will impact on policy for population-based genetic testing of women with ovarian cancer, a cancer for which the overall survival is less than 30% and few treatment options are available.